New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
08:32 EDTROSGRosetta Genomics receives two U.S. patent allowances
Rosetta Genomics announced that the company has received  two notices of allowance from the U.S. Patent and Trademark Office for Patent Applications 12/661,041 and 12/850,091. The allowed claims of 12/661,041, entitled "microRNAs and Uses Thereof," cover the composition of matter for miR-29c, as well as sequence variants, a vector and a probe comprising the same.  miR-29c is a core element in the company's lead commercial product, miRview mets2 diagnostic assay for the identification of the tumor of origin in Cancer of Unknown and Uncertain Primary. The allowed claims of 12/850,091, entitled "Viral and Viral Associated MiRNAs and Uses Thereof," cover the composition of matter for herpes simplex virus 1 miR-H3, miR-H4 and miR-H5, as well as sequence variants, a vector and a complementary sequence comprising the same.
News For ROSG From The Last 14 Days
Check below for free stories on ROSG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 10, 2014
09:03 EDTROSGRosetta Genomics receives patent for ovarian cancer treatment
Rosetta Genomics announces receipt of a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application No. 13/977,797, entitled "Compositions and Methods for Treatment of Ovarian Cancer." The patent relates to inhibition of miR-210 for the treatment of ovarian cancer. Treatment for advanced ovarian carcinoma is typically based on the combination of surgery and chemotherapy. The objective of surgical intervention in patients suffering from advanced disease is to perform cyto-reduction to minimal residual disease in the abdominal cavity. Surgery is followed by adjuvant platinum based chemotherapy. Although 80%-90% of patients initially respond to first line treatment, most will either progress during therapy or recur after complete remission. Ovarian cancer causes more deaths than any other gynecologic cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use